Urokinase-type plasminogen activator receptor in gastric cancer: Tissue expression and prognostic role

Clinical and Experimental Metastasis

Volumn 15, Issue 4, 1997, Pages 418-426

  Plebani, Mario ^a   Herszènyi, Làszlo ^a,b   Carraro, Paolo ^a   De Paoli, Massimo ^a   Roveroni, Giovanni ^a   Cardin, Romilda ^a   Tulassay, Zsolt ^b   Naccarato, Remo ^a   Farinati, Fabio ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Istituto di Medicina Interna di Padova   (Italy)

Author keywords

Gastric cancer; Plasminogen activator inhibitor type 1; Urokinase receptor; Urokinase type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROGNOSIS; STOMACH CANCER; TISSUE LEVEL;

EID: 0030787374     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018454305889     Document Type: Article

References (77)

1. Fidler IJ, 1990, Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res, 50, 6130-8.
2. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
3. Dano K, Andreasen PA, Grondahl-Hansen J, et al., 1985, Plasminogen activators, tissue degradation and cancer. Adv Cancer Res, 44, 139-266.
4. Saksela O and Rifkin DB, 1988, Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol, 4, 93-126.
5. Markus G, 1988, The relevance of plasminogen activators to neoplastic growth - a review of recent literature. Enzyme, 40, 158-72.
6. Hart IR and Saini A, 1992, Biology of tumour metastasis. Lancet, 339, 1453-7.
7. Sprengers ED and Kluft C, 1987, Plasminogen activator inhibitors. Blood, 69, 381-7.
8. Hekman CM and Loskutoff DJ, 1987, Fibrinolytic pathways and the endothelium. Semin Thromb Hemost, 13, 514-27.
9. Vassalli JD, Baccino D and Belin D, 1985, A cellular binding site for the Mr 55.000 form of the human plasminogen activator urokinase. J Cell Biol, 100, 86-92.
10. Cubellis MV, Nolli ML, Cassani G, et al., 1986, Binding of single-chain pro-urokinase to the urokinase receptor of human U937 cells. J Biol Chem, 261, 15819-22.
11. Roldan AL, Cubellis MV, Masucci MT, et al., 1990, Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface plasmin dependent proteolysis. EMBO J, 9, 467-74.
12. Ellis V, Scully MF and Kakkar VV, 1989, Plasminogen activation initiated by single-chain urokinase-type plasminogen activator: potentiation by U937 cells. J Biol Chem, 264, 2185-8.
13. Stephens R, Pollanen J, Tapiovaara H, et al., 1989, Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-hound reactants. J Cell Biol, 108, 1987-95.
14. Estreicher A, Mühlhauser J, Carpentier JL, et al, 1990, The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol, 111, 783-92.
15. Ossowski L, Clunie G, Masucci MT, et al., 1991, In vivo paracrine interaction between urokinase and ils receptor: effect on tumor cell invasion. J Cell Biol, 115, 1107-12.
16. Hollas W, Blasi F and Boyd D, 1991, Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res, 51, 3690-5.
17. Crowley CW, Cohen RL, Lucas BK, et al., 1993, Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA, 90, 5021-5.
18. Stahl A and Mueller BM, 1994, Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res, 54, 3066-71.
19. Kariko K, Kuo A, Boyd D, et al., 1993, Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res, 53, 3109-17.
20. Cohen RL, Xi XP, Crowley CW, et al., 1991, Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood, 78, 479-87.
21. Noguchi-Takino M, Endo Y, Yonemura Y, et al., 1996, Relationship between expression of plasminogen activator system and metastatic ability in human cancers. Int J Oncol, 8, 97-105.
22. Pyke C, Graem E, Ralfkier E, et al., 1993, Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res, 53, 1911-15.
23. Bianchi E, Cohen RL, Thor AT, et al., 1994, The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res, 54, 861-6.
24. Costantini V, Sidoni A, Deveglia R, et al., 1996, Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. An immunohistochemical comparison of normal, benign and malignant breast tissues. Cancer, 77, 1079-88.
25. Sappino AP, Belin D, Huarte J, et al., 1991, Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest, 88, 1073-9.
26. Pyke C, Ralfkiaer E, Ronne E, et al., 1994, Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology, 24, 131-8.
27. Heiss MM, Babic R, Allgayer H, et al., 1995, Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol, 13, 2084-93.
28. Duffy MJ, O'Grady P, Devaney D, et al., 1988, Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer (Phila.), 62, 531-3.
29. Duffy MJ, Reilly D, O'Sullivan C, et al., 1990, Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res, 50, 6827-9.
30. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al., 1993, High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res, 53, 2513-21.
31. Jänicke F, Schmitt M and Graeff H, 1991, Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost, 17, 303-12.
32. Bouchet C, Spyratos F, Martin PM, et al., 1994, Prognostic value of urokinase-type plasminogen activator (UPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer, 69, 398-405.
33. Del Vecchio S, Stopelli MP, Carriero MV, et al., 1993, Human urokinase receptor concentration in malignant and benign tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res, 53, 3198-206.
34. Foekens JA, Schmitt M, van Putten WLJ, et al., 1992, Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res, 52, 6101-5.
35. Markus G, Takita H, Camiolo SM, et al., 1980, Content and characterisation of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res, 40, 841-8.
36. Pedersen H, Brünner N, Francis D, et al., 1994, Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res, 54, 4671-5.
37. Kirchheimer JC, Köller A and Binder BR, 1984, Isolation and characterisation of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta, 797, 256-65.
38. Hasui Y, Marutsuka K, Suzumiya J, et al., 1992, The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer, 50, 871-3.
39. Landau BJ, Kwaan HC, Verrusio EN, et al., 1994, Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 in malignant human brain tumors. Cancer Res, 54, 1105-8.
40. Schmalfeldt B, Kuhn W, Reuning U, et al., 1995, Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-lype plasminogen activator, its receptor and inhibitors type 1 and 2. Cancer Res, 55, 3958-63.
41. Markus G, Camiolo SM, Kohga S, et al., 1983, Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Cancer Res, 43, 5517-25.
42. De Bruin PAF, Verspaget HW, Griffioen G, et al., 1987, Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis, 1, 57-62.
43. Sier CFM, Verspaget HW, Griffioen G, et al., 1991, Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implication of urokinase in colorectal carcinogenesis. Gastroenterology, 101, 1522-8.
44. Kirchheimer JC, Huber K, Wagner O, et al., 1987, Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol, 66, 85-9.
45. Huber K, Wojta J, Kirchheimer JC, et al., 1988, Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid. Eur J Clin Invest, 18, 595-9.
46. Tanaka N, Fukao H, Ueshima S, et al., 1991, Plasminogen activator inhibitor 1 in human carcinoma tissues. Int J Cancer, 48, 481-4.
47. Ganesh S, Sier CFM, Griffioen G, et al., 1994, Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res, 54, 4065-71.
48. Ganesh S, Sier CFM, Heerding MM, et al., 1994, Urokinase receptor and colorectal cancer survival. Lancet, 344, 401-2.
49. Sier CFM, Vloedgraven HJM, Ganesh S, et al., 1994, Inactive urokinase and increased levels of its inhibitors type 1 in colorectal cancer liver metastasis. Gastroenterology, 107, 1449-56.
50. Lau HKF, Kim M, Koo J, Chiu B, et al., 1995, Increase of a urokinase-related low-molecular-weight molecule in colorectal adenocarcinomas. Clin Exp Metastasis, 13, 492-8.
51. Mulcahy HE, Duffy MJ, Gibbons D, et al., 1994, Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet, 344, 583-4.
52. Nishino N, Aoki K, Tokura Y, et al., 1988, The urokinase type of plasminogen activator in cancer of digestive tract. Thromb Res, 50, 527-35.
53. Takai S, Yamamura M, Tanaka K, et al., 1991, Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer, 48, 20-7.
54. Umehara Y, Kimura T, Yoshida M, et al., 1991, Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncol, 30, 815-18.
55. Nakamura M, Konno H, Tanaka T, et al., 1992, Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb Res, 65, 709-19.
56. Sier CFM, Verspaget HW, Griffioen G, et al., 1993, Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut, 34, 80-5.
57. Nekarda H, Schmitt M, Ulm K, et al., 1994, Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res, 54, 2900-7.
58. Plebani M, Herszènyi L, Cardin R, et al., 1995, Cysteine and serine proteases in gastric cancer. Cancer, 76, 367-75.
59. Ganesh S, Sier CFM, Heerding MH, et al., 1996, Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer, 77, 1035-43.
60. Farinati F, Herszènyi L, Carraro P, et al., 1995, Cysteine and serine proteases: behavior in precancerous changes and prognostic value in gastric cancer. Gastroenterology, 108, A465.
61. Borrmann R, 1926, Geschwülste des Magens und Duodenums. In: Henke F, Lubarsch O, eds. Handbuch der speziellen pathologischen Anatomie und Histologie. Berlin: Springer-Verlag, pp. 864-71.
62. Laurèn P, 1965, The two histologie main types of gastric carcinoma: Diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand, 64, 31-49.
63. Sugano H, Nakamura K and Kato Y, 1982, Pathological studies of human gastric cancer. Acta Pathol Jpn, 32, 329-47.
64. Beahrs OH, Henson DE and Hutler RVP, 1992, Manual of Staging of Cancer, 4th edn. Philadelphia: JB Lippincott, pp. 63-6.
65. Bradford MA, 1976, Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
66. Roder JD, Böttcher K, Siewert JR, et al., 1993, Prognostic factors in gastric carcinoma. Cancer, 72, 2089-97.
67. Maruyama K, 1987, The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol, 22 (suppl 133), 63-8.
68. Nakamura K, Ueyama T, Yao T, et al., 1992, Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer, 70, 1030-7.
69. Reilly D, Christensen L, Duch M, et al., 1992, Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer, 50, 208-14.
70. Paoli BU and Knudson W, 1988, Tumor invasion: A consequence of destructive and compositional matrix alterations. Hum Pathol, 19, 628-39.
71. Kristensen P, Pyke C, Lund LR, et al., 1990, Plasminogen activator inhibitor type-1 in Lewis lung carcinoma. Histochemistry, 93, 559-66.
72. Montesano R, Pepper MS, Mohlesteinlein U, et al., 1990, Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelin cells expressing the middle T- oncogene. Cell, 62, 435-45.
73. Cubellis MV, Wun TC and Blasi F, 1990, Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J, 9, 1079-85.
74. Martin IG, Dion MF, Sue-Ling H, et al., 1994, Goseki histological grading of gastric cancer is an important predictor of outcome. Gut, 35, 758-63.
75. Rugge M, Sonego F, Panozzo M, et al., 1994, Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. Cancer, 73, 1127-33.
76. Ossowski L, Russo-Payne H and Wilson EL, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res, 51, 274-81.
77. Fazioli F and Blasi F, 1994, Urokinase-type plasminogen activator and its receptor: new target for anti-metastatic therapy? Trends Pharmacol Sci, 15, 25-9.